Clinical outcomes and safety of zoledronic acid in castration-resistant metastatic prostate cancer with bone metastases: real-world data from Côte d'Ivoire.
- DOI
- 10.3389/fonc.2026.1847737
- Published
- 2026
- Container
- Frontiers in oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2026.1847737,
title = {Clinical outcomes and safety of zoledronic acid in castration-resistant metastatic prostate cancer with bone metastases: real-world data from Côte d'Ivoire.},
author = {Odo BA and Kouassi KKY and Toure PGL and Gnabro GAP and Touré YL and Madiou MKA and Mbarga Amougou F and Mebiala NMP and Sessegnon FA and Nogbou AMBY and Agrigna H and Sako K and Toure M and Adoubi I},
year = {2026},
journal = {Frontiers in oncology},
doi = {10.3389/fonc.2026.1847737},
url = {https://doi.org/10.3389/fonc.2026.1847737}
}RIS
TY - JOUR TI - Clinical outcomes and safety of zoledronic acid in castration-resistant metastatic prostate cancer with bone metastases: real-world data from Côte d'Ivoire. AU - Odo BA AU - Kouassi KKY AU - Toure PGL AU - Gnabro GAP AU - Touré YL AU - Madiou MKA AU - Mbarga Amougou F AU - Mebiala NMP AU - Sessegnon FA AU - Nogbou AMBY AU - Agrigna H AU - Sako K AU - Toure M AU - Adoubi I PY - 2026 JO - Frontiers in oncology DO - 10.3389/fonc.2026.1847737 UR - https://doi.org/10.3389/fonc.2026.1847737 ER -
APA
BA, O., KKY, K., PGL, T., GAP, G., YL, T., MKA, M., F, M. A., NMP, M., FA, S., AMBY, N., H, A., K, S., M, T., & I, A. (2026). Clinical outcomes and safety of zoledronic acid in castration-resistant metastatic prostate cancer with bone metastases: real-world data from Côte d'Ivoire.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1847737
Source records
- pubmed · retrieved 2026-11-10T18:11:08.396Z